LADENBURG THALM/SH SH Boosts Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $21.00

Corvus Pharmaceuticals (NASDAQ:CRVS) had its price target hoisted by analysts at LADENBURG THALM/SH SH from $12.00 to $21.00 in a report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s target price suggests a potential upside of 281.82% from the company’s previous close.

Separately, StockNews.com upgraded shares of Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 13th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.83.

Corvus Pharmaceuticals Trading Down 4.8 %

Shares of NASDAQ:CRVS opened at $5.50 on Monday. The company’s 50 day moving average is $3.50 and its 200 day moving average is $2.45. The company has a market cap of $344.03 million, a PE ratio of -10.58 and a beta of 1.13. Corvus Pharmaceuticals has a twelve month low of $1.05 and a twelve month high of $6.15.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Tuesday, August 6th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.05. During the same quarter last year, the business earned ($0.14) earnings per share. Equities research analysts predict that Corvus Pharmaceuticals will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Corvus Pharmaceuticals by 10.6% in the first quarter. Vanguard Group Inc. now owns 1,493,357 shares of the company’s stock worth $2,658,000 after acquiring an additional 142,724 shares in the last quarter. Towerview LLC lifted its holdings in shares of Corvus Pharmaceuticals by 4.6% in the 2nd quarter. Towerview LLC now owns 400,000 shares of the company’s stock worth $728,000 after purchasing an additional 17,500 shares during the last quarter. Samlyn Capital LLC grew its position in shares of Corvus Pharmaceuticals by 160.7% during the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock worth $11,144,000 after acquiring an additional 3,774,658 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Corvus Pharmaceuticals during the second quarter worth approximately $136,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Corvus Pharmaceuticals during the second quarter valued at $44,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.